Keytruda

• 

Longer term outcomes with pembrolizumab plus axitinib combination for advanced kidney cancer

By Sophie|2021-03-09T14:39:04+00:002 Mar 2021|Drug treatments|

This Practice Update interview with Dr Monty Pal from City [...]

Read More

Comments Off on Longer term outcomes with pembrolizumab plus axitinib combination for advanced kidney cancer

• 

ASCO GU 2021: Combinations of lenvatinib plus pembrolizumab or everolimus improved survival in untreated patients with advanced kidney cancer

By Sharon Kell|2021-02-15T11:14:12+00:0015 Feb 2021|Drug treatments|

Results from the phase 3 CLEAR study, presented at the [...]

Read More

Comments Off on ASCO GU 2021: Combinations of lenvatinib plus pembrolizumab or everolimus improved survival in untreated patients with advanced kidney cancer

• 

Pembrolizumab plus lenvatinib for first-line treatment of kidney cancer shows promise

By Sharon Kell|2020-12-10T09:10:10+00:0010 Dec 2020|Uncategorized|

Results from the phase 3 KEYNOTE-581/CLEAR trial show that the [...]

Read More

Comments Off on Pembrolizumab plus lenvatinib for first-line treatment of kidney cancer shows promise

• 

Pembrolizumab plus axitinib combination accepted by NHS Scotland for first-line treatment of advanced kidney cancer

By Sharon Kell|2020-09-07T14:29:05+00:007 Sep 2020|Uncategorized|

The Sottish Medicine Consortium (SMC) have issued a final decision to [...]

Read More

Comments Off on Pembrolizumab plus axitinib combination accepted by NHS Scotland for first-line treatment of advanced kidney cancer

• 

Pembrolizumab plus axitinib combination declined for first-line treatment of advanced kidney cancer

By Sharon Kell|2020-08-27T08:45:02+00:0027 Aug 2020|Uncategorized|

The National Institute for Health and Care Excellence (NICE) have issued [...]

Read More

Comments Off on Pembrolizumab plus axitinib combination declined for first-line treatment of advanced kidney cancer

• 

ASCO 2020: Pembrolizumab/axitinib combination for the treatment of advanced kidney cancer

By Sharon Kell|2020-06-01T09:58:33+00:001 Jun 2020|Uncategorized|

Updated results from the KEYNOTE-426 study of pembrolizumab plus axitinib [...]

Read More

Comments Off on ASCO 2020: Pembrolizumab/axitinib combination for the treatment of advanced kidney cancer

• 

Promising activity of pembrolizumab plus bevacizumab for metastatic kidney cancer

By Sharon Kell|2020-03-05T10:01:41+00:005 Mar 2020|Drug treatments|

Results from a phase Ib/II study published in Journal of [...]

Read More

Comments Off on Promising activity of pembrolizumab plus bevacizumab for metastatic kidney cancer

• 

NICE draft guidance refuses pembrolizumab plus axitinib combination

By Sharon Kell|2020-02-12T15:21:43+00:0012 Feb 2020|Drug treatments|

The National Institute for Health and Care Excellence (NICE) have issued [...]

Read More

Comments Off on NICE draft guidance refuses pembrolizumab plus axitinib combination

• 

Lenvatinib plus pembrolizumab shows promise in solid tumours

By Sharon Kell|2020-01-31T17:27:07+00:0031 Jan 2020|Drug treatments|

The combination of lenvatinib plus pembrolizumab has shown promise in [...]

Read More

Comments Off on Lenvatinib plus pembrolizumab shows promise in solid tumours

• 

New first-line immunotherapy plus TKI combinations for metastatic kidney cancer

By Sharon Kell|2019-12-03T13:32:21+00:003 Dec 2019|Drug treatments|

Approval of axitinib plus pembrolizumab and axitinib plus avelumab in [...]

Read More

Comments Off on New first-line immunotherapy plus TKI combinations for metastatic kidney cancer